Medivation CMO to Retire in October, Replacement Named

SAN FRANCISCO, CA--(Marketwired - Sep 29, 2015) - Medivation, Inc. (NASDAQ: MDVN) today announced that Dr. Lynn Seely, its chief medical officer, plans to retire from her position effective October 15, 2015, after over ten years of service. She will continue as a consultant to Medivation for a period of six months, during which she will assist with the transition of her responsibilities. Mohammad Hirmand, M.D., who has been responsible for the XTANDI^® (enzalutamide) prostate cancer development program, including the pivotal clinical trials (AFFIRM and PREVAIL) which led to XTANDI’s approval for metastatic castration-resistant prostate cancer, has been promoted to interim chief medical officer and will be considered for the permanent position of chief medical officer.

“After more than a decade as Medivation’s chief medical officer, Lynn has decided to retire from her position at Medivation. As one of the first members of the Medivation team, she has made a unique contribution to the development of XTANDI and the growth of the company,” said David Hung, M.D., president and chief executive officer of Medivation. “Medivation and the community of prostate cancer patients owe her a huge debt of gratitude for her efforts, and we wish her every success in her next endeavors.”

Dr. Hirmand joined Medivation as senior director, clinical development in August 2007 and most recently served as senior vice president of clinical development and operations. Over the past eight years, he has played an instrumental role in advancing Medivation’s clinical trials, including those for enzalutamide, which led to the approval of XTANDI (enzalutamide) capsules for the treatment of metastatic castration-resistant prostate cancer. Before joining Medivation, he was a senior director of clinical development at Nuvelo, Inc. (now ARCA biopharma), where he led the clinical development department comprised of clinical operations, clinical data management and clinical sciences/medical monitor staff. Before that, he served as director of oncology development at SuperGen, Inc. (now Astex Pharmaceuticals, Inc) and as associate director of clinical research at Amgen, Inc. (formerly Tularik, Inc.), where he led clinical development efforts for Tularik’s oncology trials. Early in his career, he was a clinical scientist and manager of market development and product evaluation at Theravance Biopharma, Inc. Dr. Hirmand holds a Bachelor of Arts degree from Cornell University. Dr. Hirmand received his M.D. from Harvard Medical School.

Separately, Medivation announced the addition of two new hires. Tom Templeman, Ph.D., has joined Medivation as senior vice president of pharmaceutical operations. Lily Yang has joined Medivation as vice president, finance and accounting and will serve as Medivation’s principal accounting officer.

“Tom and Lily are great additions to our company and demonstrate our commitment to building a deep and world class management team. They bring us the leadership and experience in their respective fields that will keep Medivation at the forefront of growth and innovation in the biotech industry,” said David Hung, M.D., president and chief executive officer of Medivation. “I am joined by all their colleagues in wishing them every success.”

With over 25 years of pharmaceutical experience, Dr. Templeman previously served as vice president of manufacturing, science and technology at Hospira, as senior vice president, integrated supply chain at Liquidia Technologies and in various leadership roles at Johnson & Johnson, where he worked for 13 years in a number of capacities, most recently as general manager of Centocor Biologics, LLC and head of the global biologics supply chain. Dr. Templeman holds a Bachelor of Science degree in Biology from the University of Santa Clara and a Ph.D. from Dartmouth College and was a National Institutes of Health postdoctoral fellow at Harvard University.

Most recently, Ms. Yang served as vice president and corporate controller at Gilead Sciences, Inc. In her 12 years at Gilead, Ms. Yang led or worked in accounting, financial planning & analysis, SEC reporting, technical accounting, financial systems, strategic planning, Sarbanes-Oxley Act compliance and treasury. Previously, Ms. Yang was at General Electric and Arthur Andersen. Ms. Yang holds a Bachelor of Science degree in Accounting and Managerial Information Systems from Boston University and is a certified public accountant.

About Medivation Inc.
Medivation, Inc. is a biopharmaceutical company focused on the development and commercialization of medically innovative therapies to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their families. For more information, please visit us at http://www.medivation.com